Clinical trials: Skin Toxicity
Stevens-Johnson Syndrome, Corneal Blindness
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
The proposed study is intended to test the idea, based upon current knowledge of the biology and physiology of corneal ulceration in SJS/TENS patients who receive a keratoprosthesis, and on the known effects of infliximab on…
- Trial name
- NCT01256489
- Testing
- Infliximab
- Where
- United States
- Sponsor
- Massachusetts Eye and Ear Infirmary
Breast Cancer
TARGIT-C(Consolidation) Prospective Phase IV Study of IORT in Patients With Small Breast Cancer
This prospective, multicentric single arm phase IV study is based on the protocol of the international TARGIT-A and TARGIT-E study.
- Trial name
- TARGIT-C (NCT02290782)
- Testing
- Intraoperative radiotherapy (IORT)
- Where
- 4 sites in France, Germany
- Volunteers
- 387 people
- Sponsor
- Universitätsmedizin Mannheim
Coronary Artery Disease, Cardiac Disease
The CAROLE (CArdiac Related Oncologic Late Effects) Study
CAROLE seeks to evaluate the relationship between chest Radiation Therapy and coronary artery disease. The purpose of CAROLE is to check the heart health of women who received breast cancer treatments in the past and protect them…
- Conditions
- Coronary Artery Disease, Cardiac Disease, Cardiac Toxicity, Radiation
- Trial name
- CAROLE (NCT03235427)
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Northwell Health
Skin Toxicity
Skin Care for Cancer Patients: A Product Satisfaction Survey
This study is being done because the investigators would like to evaluate product satisfaction of three test products (product A, product B, product C) that are available at any drug store.
- Trial name
- NCT00871429
- Testing
- Lindi skin care products
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Northwestern University
Breast Cancer, Metastatic Castration-resistant Prostate Carcinoma
Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity
Docetaxel is used as a first line anti-cancer drug in the treatment of several cancers, mainly breast- and metastatic castration-resistant prostate carcinoma.
- Trial name
- LEANDOC (NCT01621425)
- Testing
- Lean body mass, Total body weight, bloodsampling
- Where
- 2 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Radboud University Medical Center
Node-positive Breast Cancer
Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
In breast cancer patients with nodal involvement, numerous studies have demonstrated that adjuvant radiation therapy reduces the risk of local recurrence, regional recurrence, and distant metastases, in addition to improving…
- Trial name
- SWIFT RT (NCT06559540)
- Testing
- Hypofractionated radiation, Ultra-hypofractionated breast/chest wall and regional nodal radiation
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Washington University School of Medicine
Vasculitis, Wegener's Granulomatosis
Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
This study will evaluate the safety and effectiveness of a staged approach to therapy for Wegener's granulomatosis and other systemic vasculitides using prednisone plus cyclophosphamide followed by methotrexate.
- Trial name
- NCT00001473
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Breast Cancer, Peripheral Neuropathy
NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Phase 2, randomized, double-blind, Placebo-Controlled, Multiple Dose Study for the treatment of Patients with Metastatic Breast Cancer.
- Trial name
- NCT04675450
- Testing
- NBP Softgel Capsules
- Volunteers
- healthy volunteers welcome
- Sponsor
- Conjupro Biotherapeutics, Inc.
Arthritis, Systemic Lupus Erythematosus
Monitoring the IMmUological TOXicity of Drugs
Several drugs and chemotherapies seem to have an impact on the immunological system. This study investigates reports of immunological toxicities, including the International classification of disease ICD-10 codes M05, M32, I78…
- Conditions
- Arthritis, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Capillary Leak Syndrome
- Trial name
- MIMUTOX (NCT03480529)
- Testing
- drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom
- Where
- 2 sites in France
- Volunteers
- 662 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Radiation Dermatitis
Trial Comparing Best Supportive Care to Aloe Vera Gel
Radiation therapy (RT) has been a component of breast cancer treatment for almost 100 years. Although initially used for the treatment of chest wall recurrences after mastectomy and for advanced inoperable disease, RT has evolved…
- Trial name
- NCT00876642
- Testing
- Aloe vera gel
- Where
- Brazil
- Volunteers
- 137 people
- Sponsor
- Marilia Medicine School
Occupational Diseases
Hazardous Substances Injuries
This clinical study aims to evaluate the effectiveness and safety of [intervention or treatment] in patients with [clinical condition].
- Trial name
- Substances (NCT07879261)
- Testing
- Retrospective Administrative Data Assessment
- Where
- Israel
- Volunteers
- 1,951 people
- Sponsor
- Sergio Gabriel Susmallian
Metastatic Melanoma, Metastatic Kidney Cancer
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
Background: Natural killer (NK) cells are large lymphocytes (a type of white blood cell) that are important in the immune response to cancer.
- Trial name
- NCT00328861
- Testing
- Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Cognitive Ability, General
Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer
RATIONALE: Radiation therapy uses high-energy x rays to kill tumor cells. Radiation therapy may cause skin reactions when patients are exposed to high-energy x rays.
- Conditions
- Breast Cancer, Cognitive Ability, General, Fatigue, Pain
- Trial name
- NCT01407770
- Testing
- DNA analysis, gene expression analysis, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Wake Forest University Health Sciences
Melanoma Stage IV, Melanoma Stage III
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
- Conditions
- Melanoma Stage IV, Melanoma Stage III, Immunotherapy, Toxicity, Drug
- Trial name
- NCT05652673
- Testing
- nivolumab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center
Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced
SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a severe adverse drug reaction, characterized by extensive skin detachment.
- Conditions
- Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced, Toxic Epidermal Necrolysis Due to Drug
- Trial name
- NCT06522048
- Testing
- Observational studies do not require intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chao Ji
Mesenchymal Stromal Cells, Psoriasis
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
The purpose of this study is to evaluate the safety and efficacy of Adipose-derived Mesenchymal Stem Cells (AD-MSCs) with moderate to severe psoriasis. Any adverse events related to AD-MSCs infusion will be monitored.
- Conditions
- Mesenchymal Stromal Cells, Psoriasis, Drug Toxicity, Drug Effect
- Trial name
- ADMSP (NCT03265613)
- Testing
- adipose-derived multipotent mesenchymal stem cells
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Metastatic Breast Cancer, 70 Years Old Patients and Over
Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.
GERICO 09/0907 is a Phase II multicentric trial evaluating the toxicity and activity of the combination of lapatinib and capecitabine in locally advanced or metastatic breast cancer over expressing HER2 for patients aged ≥ 70 who…
- Conditions
- Metastatic Breast Cancer, 70 Years Old Patients and Over, After One Line of Chemotherapy With Trastuzumab
- Trial name
- GERICO09 (NCT01262469)
- Testing
- lapatinib + capecitabine
- Where
- 20 sites in France
- Volunteers
- 4 people
- Sponsor
- UNICANCER
Breast Neoplasms
Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program
The aim of this study is to determine if therapeutic exercise before anticancer treatment will mitigate the onset or extent of cardiotoxicity comparing to therapeutic exercise performed during anticancer treatment.
- Trial name
- ATOPE (NCT03787966)
- Testing
- ATOPE-B, ATOPE-I
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Universidad de Granada
Metastatic Solid Tumor, Locally Advanced Solid Tumor
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
The goal of this clinical trial is to learn if using topical tretinoin will help patients with solid tumors who are experiencing an acneiform rash as a side effect of their treatment.
- Trial name
- FACE (NCT06358677)
- Testing
- Topical Tretinoin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Utah
Breast Cancer, Colorectal Cancer
Association of Capecitabine Pharmacokinetics and Toxicity With Aging
This is a multi-centre prospective non-interventional study designed to evaluate the effects of patient age on the pharmacokinetics of capecitabine and its metabolites 5'DFCR, 5'DFUR, and 5-FU.
- Trial name
- NCT03465202
- Testing
- Capecitabine
- Volunteers
- 100 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust